Phase 2
Completed N=15
Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease
Source: ClinicalTrials.gov NCT05422885 ↗Enrolled (actual)
15
Serious AEs
6.7%
Results posted
Mar 2025
Primary outcomePrimary: Neurovascular Coupling — 0.68; 0.26; 0.80 cm/s
Summary
The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neurovascular Coupling |
0.68; 0.26; 0.80 | — |
| PRIMARY Executive Function |
80.6; 75.0; 63.4 | — |
| PRIMARY Gait Speed |
0.87; 0.85; 0.87 | — |
| PRIMARY Montreal Cognitive Assessment (MoCA) Score |
23; 25; 24 | — |
| SECONDARY Physical Performance |
9; 9; 9 | — |
| SECONDARY Mobility |
14.2; 13.9; 13.6 | — |
| SECONDARY Grip Strength |
23.5; 22.7; 23.6 | — |
| SECONDARY Gait Speed During Cognitive Task |
0.76; 0.75; 0.78 | — |
| SECONDARY P16 ink4a Expression in CD3 Positive Cells |
10.6; 9.4 | — |
| SECONDARY SASP Factors in Blood and Urine |
458.5; 541.6 | — |
| SECONDARY SASP Factors in Blood and Urine |
458.5; 541.6 | — |
Eligibility Criteria
Inclusion Criteria
- Men and women >/= 65 years
- Ambulatory,
- Community dwelling,
- Slow gait speed (<1 m/second),
- Mild Cognitive Impairment (Telephone MoCA score <21, which is indicative of cognitive impairment)
Exclusion Criteria, or as per clinical judgment:
- Telephone MoCA score <10 points
- Unwilling to take study medications or follow study protocol
- Inability to independently perform Katz Activities of Daily Living (ADLs),
- Allergies to Dasatinib or Quercetin,
- Hospitalization within 6 months,
- Unstable coronary artery disease (myocardial infarction within 6 months or angina),
- Stroke or transient ischemic attack in the past 6 months,
- Chronic heart failure,
- Current or chronic history of liver disease,
- Neurodegenerative disease including Parkinson's disease,
- Anemia,
- Chronic renal disease,
- Drug or alcohol abuse in the last 5 years,
- QTc prolongation,
- Thrombocytopenia,
- Neutropenia,
- Prolonged prothrombin time or INR,
- Indications of current fluid retention,
- History or current diagnosis of pulmonary hypertension,
- Inability to insonate the middle cerebral artery through a temporal bone window on at least one side using transcranial Doppler ultrasound, or
- Chronic use of any of the following medications: anti-arrhythmic medications, antipsychotics, anxiolytics, anti-platelet or anti-coagulant medications other than aspirin, quinolone antibiotics, or drugs metabolized by the same liver enzymes as Quercetin or Dasatinib.
Data sourced from ClinicalTrials.gov (NCT05422885). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.